公开(公告)号：US20190331697A1

公开(公告)日：2019-10-31

申请号：US16381158

申请日：2019-04-11

Applicant: Incyte Corporation

Inventor： Michael D. Howell ,  Hao Liu ,  Michael A. Pratta

IPC: G01N33/68 ,  A61P37/06 ,  A61K45/06 ,  A61K31/573 ,  A61K31/519

Abstract: Biomarkers are provided that are predictive of a subject's responsiveness to a therapy comprising a JAK inhibitor. The biomarkers, compositions, and methods described herein are useful in selecting appropriate treatment modalities for a subject having, suspected of having, or at risk of developing Graft-Versus-Host Disease.

公开(公告)号：US12099068B2

公开(公告)日：2024-09-24

申请号：US17749376

申请日：2022-05-20

Applicant: Incyte Corporation

Inventor： Michael D. Howell ,  Hao Liu ,  Michael A. Pratta

IPC: G01N33/68 ,  A61K31/519 ,  A61K31/573 ,  A61K45/06 ,  A61P37/06

CPC classification number: G01N33/6893 ,  A61K31/519 ,  A61K31/573 ,  A61K45/06 ,  A61P37/06 ,  G01N2800/245 ,  G01N2800/52 ,  G01N2800/60

Abstract: Biomarkers are provided that are predictive of a subject's responsiveness to a therapy comprising a JAK inhibitor. The biomarkers, compositions, and methods described herein are useful in selecting appropriate treatment modalities for a subject having, suspected of having, or at risk of developing Graft-Versus-Host Disease.

公开(公告)号：US20230027606A1

公开(公告)日：2023-01-26

申请号：US17749376

申请日：2022-05-20

Applicant: Incyte Corporation

Inventor： Michael D. Howell ,  Hao Liu ,  Michael A. Pratta

IPC: G01N33/68 ,  A61P37/06 ,  A61K31/519 ,  A61K31/573 ,  A61K45/06

Abstract: Biomarkers are provided that are predictive of a subject's responsiveness to a therapy comprising a JAK inhibitor. The biomarkers, compositions, and methods described herein are useful in selecting appropriate treatment modalities for a subject having, suspected of having, or at risk of developing Graft-Versus-Host Disease.

公开(公告)号：US11372003B2

公开(公告)日：2022-06-28

申请号：US16381158

申请日：2019-04-11

Applicant: Incyte Corporation

Inventor： Michael D. Howell ,  Hao Liu ,  Michael A. Pratta

IPC: A61P37/06 ,  A61K31/519 ,  A61K31/573 ,  A61K45/06 ,  G01N33/68

Abstract: Biomarkers are provided that are predictive of a subject's responsiveness to a therapy comprising a JAK inhibitor. The biomarkers, compositions, and methods described herein are useful in selecting appropriate treatment modalities for a subject having, suspected of having, or at risk of developing Graft-Versus-Host Disease.